Targeting GRP75 improves HSP90 inhibitor efficacy by enhancing p53-mediated apoptosis in hepatocellular carcinoma

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Guo, Weiwei ^a   Yan, Lichong ^a   Yang, Ling ^a   Liu, Xiaoyu ^a   E, Qiukai ^a   Gao, Peiye ^a   Ye, Xiaofei ^a   Liu, Wen ^a   Zuo, Ji ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 ETHYL 2 [[3 ETHYL 5 (3 METHYLBENZOTHIAZOLIN 2 YLIDENE) 4 OXOTHIAZOLIDIN 2 YLIDENE]METHYL]PYRIDINIUM CHLORIDE; GLUCOSE REGULATED PROTEIN 75; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; PROTEIN P53; TANESPIMYCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER MODEL; CARCINOMA CELL; CONTROLLED STUDY; CYTOPLASM; DRUG POTENTIATION; DRUG TARGETING; FEMALE; GENE INDUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZOQUINONES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; FEMALE; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; LIVER NEOPLASMS; MEMBRANE PROTEINS; MICE; MICE, NUDE; PROTEIN TRANSPORT; PYRIDINES; THIAZOLES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84898462646     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085766     Document Type: Article

References (50)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
2. Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, et al. (2010) World Gastroenterology Organization, Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol 44: 239-245.
3. Soti C, Nagy E, Giricz Z, Vigh L, Csermely P, et al. (2005) Heat shock proteins as emerging therapeutic targets. Br J Pharmacol 146: 769-780. (Pubitemid 41622243)
4. Maloney A, Workman P (2002) HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2: 23-24.
5. Gooljarsingh LT, Fernandes C, Yan K, Zhang H, Grooms M, et al. (2006) A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues. Proc Natl Acad Sci U S A 103: 7625-7630.
6. Pascale RM, Simile MM, Calvisi DF, Frau M, Muroni MR, et al. (2005) Role of HSP90, CDC37, and CRM1 as modulators of P16 (INK4A) activity in rat liver carcinogenesis and human liver cancer, Hepatology 42: 1310-1319. (Pubitemid 43260033)
7. Dimopoulos MA, Mitsiades CS, Anderson KC, Richardson PG (2011) Tanespimycin as antitumor therapy. Clin Lymphoma Myeloma Leuk 11: 17-22.
8. Langer CJ, Mok T, Postmus PE (2013) Targeted agents in the third 2/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). Cancer Treat Rev 39: 252-260.
9. Pimienta G, Herbert KM, Regan L (2011) A compound that inhibits the HOP-Hsp90 complex formation and has unique killing effects in breast cancer cell lines. Mol Pharm 8: 2252-2261.
10. Sharp SY, Roe SM, Kazlauskas E, Cikotienė I, Workman P, et al. (2012) Co-crystalization and in vitro biological characterization of 5-aryl-4-(5-substituted-2-4-dihydroxyphenyl)-1,2,3-thiadiazole hsp90 inhibitors. PLoS One 7: e44642.
11. Ayrault O, Godeny MD, Dillon C, Zindy F, Fitzgerald P, et al. (2009) Inhibition of Hsp90 via 17-DMAG induces apoptosis in a p53-dependent manner to prevent medulloblastoma. Proc Natl Acad Sci U S A 106: 17037-17042.
12. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101. (Pubitemid 40262113)
13. Vadlakonda L, Dash A, Pasupuleti M, Anil Kumar K, Reddanna P (2013) The paradox of Akt-mTOR interactions. Frontiers in oncology 20: 165.
14. Lu WJ, Lee NP, Kaul SC, Lan F, Poon RT, et al. (2011) Mortalin-p53 interaction in cancer cells is stress dependent and constitutes a selective target for cancer therapy. Cell Death Differ 18: 1046-1056.
15. Ornatsky OI, Connor MK, Hood DA (1995) Expression of stress proteins and mitochondrial chaperonins in chronically stimulated skeletal muscle. Biochem J 311: 119-123.
16. Xu J, Xiao HH, Sartorelli AC (1999) Attenuation of the induced differentiation of HL-60 leukemia cells by mitochondrial chaperone HSP70. Oncol Res 11: 429-435.
17. Pizzatti L, Sa LA, de Souza JM, Bisch PM, Abdelhay E (2006) Altered protein profile in chronic myeloid leukemia chronic phase identified by a comparative proteomic study. Biochim Biophys Acta 1764: 929-942. (Pubitemid 43732347)
18. Takano S, Wadhwa R, Yoshii Y, Nose T, Kaul SC, et al. (1997) Elevated levels of mortalin expression in human brain tumors. Exp Cell Res. 237: 38-45. (Pubitemid 27528026)
19. Rozenberg P, Kocsis J, Saar M, Prohaszka Z, Fust G, et al. (2013) Elevated levels of mitochondrial mortalin and cytosolic HSP70 in blood as risk factors in patients with colorectal cancer. Int J Cancer 133: 514-518.
20. Wadhwa R, Takano S, Kaur K, Deocaris CC, Pereira-Smith OM, et al. (2006) Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis. Int J Cancer 118: 2973-80.
21. Yi X, Luk JM, Lee NP, Peng J, Leng X, et al. (2008) Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence. Mol Cell Proteomics 7: 315-325. (Pubitemid 351298446)
22. Wadhwa R, Takano S, Kaur K, Deocaris CC, Pereira-Smith OM, et al. (2006) Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis. Int J Cancer 118: 2973-2980.
23. Kaul SC, Aida S, Yaguchi T, Kaur K, Wadhwa R (2005)Activation of wild type p53 function by its mortalin-binding, cytoplasmically localizing carboxyl terminus peptides. J Biol Chem 280: 39373-39379. (Pubitemid 41713894)
24. Kaul SC, Reddel RR, Mitsui Y, Wadhwa R (2001) An N-terminal region of mot-2 binds to p53 in vitro. Neoplasia. 3: 110-114. (Pubitemid 32410351)
25. Wadhwa R, Yaguchi T, Hasan MK, Mitsui Y, Reddel RR, et al. (2002) Hsp70 family member, mot-2/mthsp70/GRP75, binds to the cytoplasmic sequestration domain of the p53 protein. Exp Cell Res 274: 246-253.
26. Wadhwa R, Takano S, Taira K, Kaul SC (2004) Reduction in mortalin level by its antisense expression causes senescence-like growth arrest in human immortalized cells. J Gene Med 6: 439-444. (Pubitemid 40228060)
27. Wadhwa R, Sugihara T, Yoshida A, Nomura H, Reddel RR, et al. (2000) Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function. Cancer Res 60: 6818-6821. (Pubitemid 32059144)
28. Lang SA, Moser C, Gaumann A, Klein D, Glockzin G, et al. (2007) Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth. Clin Cancer Res 13: 6459-6468. (Pubitemid 350075036)
29. Yang L, Liu X, Hao J, Yang Y, Zhao M, et al. (2008) Glucose-regulated protein 75 suppresses apoptosis induced by glucose deprivation in PC12 cells through inhibition of Bax conformational change. Acta Biochim Biophys Sin 40: 339-48. (Pubitemid 351572115)
30. Breinig M, Caldas-Lopes E, Goeppert B, Malz M, Rieker R, et al. (2009) Targeting heat shock protein 90 with non-quinone inhibitors: a novel chemotherapeutic approach in human hepatocellular carcinoma. Hepatology 50: 102-112.
31. Beliveau A, Yaswen P (2007) Soothing the watchman: telomerase reduces the p53-dependent cellular stress response. Cell Cycle 6: 1284-1287. (Pubitemid 47327957)
32. Liu M, Li C, Pazgier M, Li C, Mao Y, et al. (2010) D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms. Proc Natl Acad Sci U S A 107: 14321-14326.
33. Kaul SC, Reddel RR, Mitsui Y, Wadhwa R (2001) An N-terminal region of mot-2 binds to p53 in vitro. Neoplasia 3: 110-114. (Pubitemid 32410351)
34. Neckers L, Workman P (2012) Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 18: 64-76.
35. Maloney A, Clarke PA, Naaby-Hansen S, Stein R, Koopman JO, et al. (2007) Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res 67: 32339-32353.
36. Sharp S, Workman P (2006) Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res 95: 323-348. (Pubitemid 44088424)
37. Powers MV, Clarke PA, Workman P (2008) Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 14: 250-262.
38. Deocaris CC, Widodo N, Shrestha BG, Kaur K, Ohtaka M, et al. (2007) Mortalin sensitizes human cancer cells to MKT-077-induced senescence. Cancer Lett 252: 259-269. (Pubitemid 46809793)
39. Wade M, Wang YV, Wahl GM (2010) The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol (20): 299-309.
40. Ghobrial IM, Witzig TE, Adjei AA (2005) Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 55: 178-194. (Pubitemid 40826487)
41. Altomare DA, Testa JR (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24: 7455-7464. (Pubitemid 41637985)
42. Liao Y, Hung MC (2010) Physiological regulation of Akt activity and stability. Am J Transl Res 2: 19-42.
43. Lowe SW, Cepero E, Evan G (2004) Intrinsic tumour suppression. Nature 432: 307-315. (Pubitemid 39551658)
44. Drakos E, Atsaves V, Li J, Leventaki V, Andreeff M, et al. (2009) Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma. Leukemia 23: 784-790.
45. Hussain SP, Schwank J, Staib F, Wang XW, Harris CC (2007) TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 26: 2166-2176. (Pubitemid 46536641)
46. Teufel A, Staib F, Kanzler S, Weinmann A, Schulze-Bergkamen H, et al. (2007) Genetics of hepatocellular carcinoma. World J Gastroenterol 13: 2271-2282. (Pubitemid 46860727)
47. Bressac B, Kew M, Wands J, Ozturk M (1991) Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350: 429-431. (Pubitemid 21912246)
48. Scorsone KA, Zhou YZ, Butel JS, Slagle BL (1992) p53 mutations cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinomas from China. Cancer Res 52: 1635-1638.
49. Lu WJ, Lee NP, Kaul SC, Lan F, Poon RT, et al. (2011) Induction of mutant p53-dependent apoptosis in human hepatocellular carcinoma by targeting stress protein mortalin. Int J Cancer 129: 1806-1814.
50. Propper DJ, Braybrooke JP, Taylor DJ, Lodi R, Styles P, et al. (1999) Phase I trial of the selective mitochondrial toxin MKT077 in chemo-resistant solid tumours. Ann Oncol 10: 923-927. (Pubitemid 29424571)